Holen Sie sich die Stockscreener-App
8.23
4.44%
0.35
Handel nachbörslich:
7.30
-0.93
-11.30%
Schlusskurs vom Vortag:
$7.88
Offen:
$7.97
24-Stunden-Volumen:
11,965
Relative Volume:
0.22
Marktkapitalisierung:
$77.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-129.41M
KGV:
-0.3416
EPS:
-24.0922
Netto-Cashflow:
$-51.97M
1W Leistung:
-2.37%
1M Leistung:
-26.91%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$7.8091
$8.23
1-Wochen-Bereich:
$7.8091
$9.36
52-Wochen-Spanne:
$4.21
$14.21
Leonabio Inc Stock (LONA) Company Profile
Firmenname
Leonabio Inc
Sektor
Branche
Telefon
(425) 620-8501
Adresse
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
8.23 | 79.38M | 0 | -129.41M | -51.97M | -24.09 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-09-19 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-09-04 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-09-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-10-17 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-06-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | Herabstufung | Jefferies | Buy → Hold |
| 2022-06-23 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Eingeleitet | BTIG Research | Buy |
| 2022-04-21 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Goldman | Neutral |
| 2020-10-13 | Eingeleitet | Goldman | Buy |
| 2020-10-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-13 | Eingeleitet | Jefferies | Buy |
| 2020-10-13 | Eingeleitet | Stifel | Buy |
Alle ansehen
Leonabio Inc Aktie (LONA) Neueste Nachrichten
LONA Q1 2026 Earnings: EPS Surprises Above Estimates Amid Pre-Revenue PhaseGuidance Accuracy Score - newsline.com
LONA Q1 2026 Earnings: Narrowed Loss Exceeds Expectations as Cost Discipline ContinuesEarnings Trend Analysis - newsline.com
LeonaBio (LONA) Holds Steady Near Support as Sector Sentiment WeighsLow Beta Factor - newsline.com
LeonaBio names brelgometon as INN for ALS drug candidate ATH-1105 - Investing.com UK
LeonaBio names brelgometon as INN for ALS drug candidate ATH-1105 By Investing.com - Investing.com South Africa
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit - The Manila Times
LONA Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress in Pipeline Despite Market HeadwindsMargin Improvement Report - The Legal Advocate
LeonaBio Inc. (LONA) Q1 2026 Earnings: Surprise EPS Beat Signals Progress Despite Revenue GapEstimate Uncertainty - The Legal Advocate
LeonaBio Gets $20 Price Target Ahead of June Pipeline Test - Bez Kabli
LeonaBio Inc. (LONA) Rises 1.45% as Shares Approach Key Resistance at $10.3Stock News - The Legal Advocate
LONA Initiated Coverage by Piper Sandler -- Rating Set to Overwe - GuruFocus
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June - GlobeNewswire
Piper Sandler initiates LeonaBio stock with overweight rating - Investing.com
Piper Sandler initiates LeonaBio stock with overweight rating By Investing.com - Investing.com Canada
LeonaBio Inc. (LONA) Q1 2026 Earnings: EPS Surprise Provides Bright Spot Amid Revenue Absence and Stock DeclineCash Flow Report - The Legal Advocate
LeonaBio Inc. (LONA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ReactionOperating Income Trends - The Legal Advocate
LeonaBio Inc. (LONA) Q1 2026 Earnings: Narrower-Than-Expected Loss Buoyed by R&D ProgressEarnings Deceleration Risk - newsline.com
LeonaBio Inc. (LONA) Q1 2026 Earnings: Narrowing Losses Signal Operational DisciplineRetail Earnings Report - Newser
Why Is LeonaBio, Inc. (LONA) Stock Up Today? - Meyka
Why Is LeonaBio, Inc. (LONA) Stock Down Today? - Meyka
ADAR1, Daniel Schneeberger disclose 727,481 shares in LeonaBio (ATHA) - Stock Titan
LeonaBio (ATHA) details 2026 director, auditor and Say-on-Pay votes - Stock Titan
Mizuho Securities Maintains LeonaBio(LONA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Dividend HistoryLeonaBio, Inc. (LONA) - Zacks Investment Research
LONA: LeonaBio, Inc.Insider Transations - Zacks Investment Research
MSN Money - MSN
LeonaBio (LONA) director receives 56,000 stock options at $9.63 strike - Stock Titan
Director at LeonaBio (LONA) granted 56,000 stock options - Stock Titan
Option grant gives LeonaBio (LONA) director 56,000 shares at $9.63 - Stock Titan
Natalie Holles named LeonaBio (LONA) director in initial Form 3 - Stock Titan
LeonaBio (LONA) director Peter B. Silverman files initial Form 3 - Stock Titan
LeonaBio (LONA) director Callori Fred files baseline Form 3 ownership report - Stock Titan
Perceptive Advisors (ATHA) caps LeonaBio stake at 19.99% and gains board seat - Stock Titan
LeonaBio (NASDAQ: ATHA) widens loss as R&D ramps for lasofoxifene and ALS drug - Stock Titan
LeonaBio (NASDAQ: ATHA) widens Q1 loss while funding late-stage trials - Stock Titan
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
LeonaBio reshapes board with 3 hires as long-serving director exits - Stock Titan
LeonaBio John Fluke Retires, Effective May 4 >LONA - Moomoo
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D. - Weekly Voice
LeonaBio Enhances Board of Directors with Appointments of - GlobeNewswire
LeonaBio, Inc. (LONA) Stock Forecast 2027, 2031 & 7-Year Price Prediction | Meyka AI - Meyka
How sustainable is LeonaBio (LONA) profit margins? (Selling Pressure) 2026-05-06Hot Market Picks - newser.com
LONA Earnings History & Surprises | EPS & Revenue Results | LEONABIO INC (NASDAQ:LONA) - ChartMill
Finanzdaten der Leonabio Inc-Aktie (LONA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Leonabio Inc-Aktie (LONA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Litton Mark James | PRESIDENT and CEO |
Mar 04 '26 |
Sale |
5.37 |
5,156 |
27,688 |
57,926 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
3,900 |
0 |
16,757 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
906 |
4,865 |
15,851 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 03 '26 |
Option Exercise |
0.00 |
5,726 |
0 |
19,704 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 04 '26 |
Sale |
5.37 |
1,328 |
7,131 |
18,376 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
5,856 |
0 |
26,537 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,359 |
7,298 |
25,178 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
7,418 |
0 |
17,607 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,720 |
9,236 |
15,887 |
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):